“The problem facing our biomedical industry has been that most vaccine and drug candidates needed to be sent overseas to be produced in large quantities for clinical trials, adding burdensome costs that have crushed many Australian businesses and researchers as the invention languishes on the lab bench," saod CSIRO chief executive Dr Larry Marshall.
CSIRO opens 'missing link' lab to develop Australian vaccine pipeline
August 12, 2022 Latest NewsBioPharma
Latest Video
New Stories
-
Frustrated minister encourages an early negotiation of new agreements
May 14, 2026 - - Latest News -
Long-term study finds continuing Mounjaro helps maintain weight loss
May 14, 2026 - - Latest News -
GBMA welcomes Budget pathway to increasing biosimilar uptake
May 14, 2026 - - Latest News -
There are a number of reasons to criticise the minister on the PBS, but he is right to be annoyed about this
May 14, 2026 - - Latest News -
Disappointment for diabetes advocates in response to Government budget silence
May 13, 2026 - - Latest News -
Updated forecast highlights the real risk of relying on these numbers
May 13, 2026 - - Latest News -
Baxter and MTAA launch Australian Healthcare Manufacturing Leaders Network
May 13, 2026 - - Latest News
